Venclose

Venclose is a medical technology company that develops technologies for the treatment of chronic venous diseases using radio frequency ablations.

History

2021: Becton & Dickinson bought Venclose

In early December 2021, Becton & Dickinson announced the purchase of Venclose for an undisclosed amount. This deal brings Becton & Dickinson to the new treatment market for varicose veins.

Varicose veins are one aspect of a broader condition known as chronic venous insufficiency, which affects up to 40% of women and 17% of men in. USA Malfunction of the valves in the vessels themselves can cause congestion blood in the legs, resulting in increased, tortuous and sometimes painful veins. The Venclose intervention uses a radiofrequency ablation catheter that is inserted into the damaged vein and supplies heat to help shorten and close the blood vessel, and after completion of the procedure, blood is naturally redirected to nearby healthy veins.

Becton & Dickinson acquired Venclose

Venclose also offers treatment for incompetent perforated veins that were approved by the U.S. Food and Drug Administration (FDA) in October 2021 and fall into a separate category of veins that can cause more serious symptoms of chronic venous insufficiency, such as painful leg ulcers.

According to Becton & Dickinson, radiofrequency ablation is the preferred treatment for chronic venous insufficiency and reduces pain and bruising compared to external, laser treatments for varicose veins. In addition, the system from Venclose, available in various medical institutions in the United States and Europe, is capable of delivering heat over two different lengths of the same catheter. Thanks to the heating zones of 2.5 cm and 10 cm, the device can ablate both short and long segments of veins, while covering a larger area in a shorter time compared to competitors with smaller devices.

The acquisition will add in-hospital stents to Becton & Dickinson's current catalogue of venous procedures to eliminate obstructions and vein injuries, as well as a large blood sampling business based on Vacutainer's widespread product line. According to Becton & Dickinson President Paddy O'Brien on peripheral interventions, the deal will also help the company switch to new treatments for veins.^[1]

Notes